The Impact of Tamoxifen and Aromatase Inhibitors on Platelet Proteins

N/ACompletedNCT01341171

University of Vermont30 enrolled

Overview

Single phlebotomy study involving women receiving tamoxifen or aromatase inhibitor therapy.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Breast Cancer

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * women routinely taking tamoxifen or aromatase inhibitor therapy as prescribed by their oncologist Exclusion Criteria: * Use of heparin, warfarin

Locations (1)

University of Vermont

Burlington, Vermont, United States

Outcomes

Primary Outcomes

Angiogenic Protein levels

Time frame: following 6 months of therapy

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.